Imaging Endpoints (IE) and ImaginAb announced that after collaborating for nearly a decade they have entered into a license agreement for IE to directly offer clinical doses of ImaginAb’s CD8 investigational ImmunoPET (zirconium Zr 89 crefmirlimab berdoxam) imaging agent for clinical trials as part of Imaging Endpoints’ industry-leading imaging CRO services.
Also Read: RxBIO Launches Neogen Plasma Skin Rejuvenation in the USA – Neogen Plasma Brings a Unique Solution
ImagingEndpoints is the world’s largest oncology-focused imaging’s CRO (“iCRO”) and has partnered with ImaginAb over the past decade to assist in the development of zirconium Zr 89 crefmirlimab berdoxam. The partnership has included ImagingEndpoints conducting all of ImaginAb’s sponsored clinical trials and acting as the Imaging CRO for zirconium Zr 89 crefmirlimab berdoxam trials conducted throughout the biopharmaceutical industry.
This new agreement will enable ImagingEndpoints to supply clinical doses of ImaginAb’s CD8 ImmunoPET agent directly to biopharmaceutical companies conducting clinical trials, while continuing to provide the world’s leading experience, expertise and services to conduct trials that benefit from CD8 imaging.
Dr. Korn, Founder and Chief Medical Officer of ImagingEndpoints, said: “We are pleased to expand our partnership with ImaginAb to now provide its CD8 Imaging Agent directly to BioPharma Companies. We are the most experienced advocates and early adopters of the benefits of advanced, non-invasive biomarkers, such as zirconium Zr 89 crefmirlimab berdoxam, in both early and late-stage oncology trials. We believe that this agreement provides another value-added service to further strengthen our position as the world’s most respected Imaging CRO in oncology.”
Ian Wilson, CEO of ImaginAb, said: “This new agreement is an exciting expansion of our long-standing relationship with ImagingEndpoints, and we are confident that our partnership with ImagingEndpoints will continue to bring the best of both businesses together, offering the potential benefits of our investigational CD8 ImmunoPET imaging agent coupled with the vast experience of ImagingEndpoints in deploying the agent in clinical trials.”